PHARMX TECHNOLOGIES LIMITED (PHX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PHX

PHX - PHARMX TECHNOLOGIES LIMITED

FNArena Sector : Healthcare
Year End: June
GICS Industry Group : Software & Services
Debt/EBITDA: N/A
Index:

PharmX Technologies provides digital ordering and invoicing infrastructure connecting pharmacies with wholesalers and suppliers across A&NZ. Its platform helps pharmacies purchase stock and manage orders, while providing suppliers with online sales channels and data analytics. Revenue comes from supplier account and transaction-volume fees.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.068

10 Nov
2026

0.004

OPEN

$0.07

6.25%

HIGH

$0.07

1,096,752

LOW

$0.07

TARGET
$0.20

+0.20 change from previous day

 194.1% upside
FNARENA'S MARKET CONSENSUS FORECASTS
PHX: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx N/A - 0.5 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-0.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx7.6 M
Book Value Per Share xxxxxxxxxxxxxxx3.5
Net Operating Cash Flow xxxxxxxxxxxxxxx0.8 M
Net Profit Margin xxxxxxxxxxxxxxx-23.97 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-9.31 %
Return on Invested Capital xxxxxxxxxxxxxxx-9.13 %
Return on Assets xxxxxxxxxxxxxxx-7.92 %
Return on Equity xxxxxxxxxxxxxxx-9.31 %
Return on Total Capital xxxxxxxxxxxxxxx-10.28 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx0.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx2 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxxxxx3.68

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx2.1 M
Capex % of Sales xxxxxxxxxxxxxxx27.62 %
Cost of Goods Sold xxxxxxxxxxxxxxx8 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx2 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

11/11/2026

1

Initiation of coverage with Speculative Buy

$0.20

194.12%

Bell Potter initiates coverage of PharmX Technologies with a Speculative Buy and 20c target price.

PharmX has developed a pharmacy technology platform connecting around 99% of Australian pharmacies with suppliers, wholesalers and technology providers.

The transition to an AI-native cloud platform introduces volume-based transaction fees, replacing legacy account-based charges and offering a significant revenue opportunity, the analyst believes.

Sigma Healthcare ((SIG)) generates around 35% of revenue, and has renewed its contract for five years with an established strategic alliance, and the potential to acquire up to 19.9% of the company, the broker details.

A potential partnership could generate $30m–50m in annualised revenue for PharmX over the agreement period.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.50 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of minus -0.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

11/11/2026

1

Initiation of coverage with Buy

$0.11

61.76%

Moelis initiates coverage on PharmX Technologies with a Buy rating and a $0.11 target price.

Moelis highlights the company's position as critical infrastructure connecting 99% of A&NZ pharmacies, facilitating approximately $26bn of annual network transaction volume.

The analyst notes that revenue growth and monetisation will be driven by a mix shift from fixed Gateway EDI fees to volume-linked variable fees generated by Relay EDI and the new Marketplace platform.

The strategic alliance with Sigma Healthcare ((SIG)), which includes a 10% equity stake and designates the company as the preferred EDI provider for the Sigma and Chemist Warehouse networks, is seen as validation for the platform, also providing significant expansion optionality.

Moelis estimates strong operating leverage as high-margin variable revenues scale against a stable cost base, forecasting positive free cash flow generation by FY28.

FORECAST
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.41 cents.
Moelis forecasts a full year FY28 dividend of 0.00 cents and EPS of minus -0.24 cents.
Access Extra Coverage Research History >

PHX STOCK CHART

FNArena News on PHX

1
Australian Broker Call *Extra* Edition – Nov 11, 2026

10:30 AM - Daily Market Reports

Latest Healthcare News

1
Strong ResMed Result Comes With Caveats

Nov 03 2026 - Australia
2
Vitrafy Eyes US Blood Breakthrough

Oct 06 2026 - Small Caps
3
Telix Aims For A Strategic Isotope Supply Chain

Sep 24 2026 - Australia
4
Treasure Chest: Healthcare Upgrades

Sep 17 2026 - Treasure Chest
5
Undervalued Catapult Sports Plays A Bigger Game

Sep 16 2026 - Small Caps
6
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
7
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
8
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
9
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest
10
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia